FDA Approves Amgen's UPLIZNA® (inebilizumab-cdon) for Generalized Myasthenia Gravis (gMG), Expanding Treatment Options for Patients Living with Autoimmune Neuromuscular Disease [Yahoo! Finance]
Amgen (NASDAQ:AMGN) was given a new $304.00 price target on by analysts at Morgan Stanley.
FDA APPROVES UPLIZNA® FOR ADULTS WITH GENERALIZED MYASTHENIA GRAVIS [Yahoo! Finance]
FDA APPROVES UPLIZNA® FOR ADULTS WITH GENERALIZED MYASTHENIA GRAVIS
Amgen (NASDAQ:AMGN) had its price target raised by analysts at Wells Fargo & Company from $300.00 to $325.00. They now have an "equal weight" rating on the stock.